Search This Blog

Tuesday, June 17, 2025

'ACIP, CDC, and Insurance Coverage of Vaccines in the US'

 As the Trump administration moves to institute changes to the process by which vaccines are recommended for the U.S. public, as well as the actual recommendations themselves1, consumers could lose access to no-cost health insurance coverage of vaccines. This is due to the fact that several laws and regulations tie such coverage to recommendations made by the Advisory Committee on Immunization Practices (ACIP) and/or those made by the Director of the Centers for Disease Control and Prevention (CDC). ACIP is a federal advisory committee established in 1964 to provide advice and guidance to the CDC Director on the use of vaccines for the public. The CDC Director reviews recommendations made by ACIP, and if adopted, they are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR). ACIP also is charged with establishing and revising the list of vaccines used for the Vaccines for Children Program. The CDC Director, or Secretary of HHS, can choose not to adopt an ACIP recommendation, to modify it, or to make their own recommendations and, in most, but not all cases, the HHS decision ultimately determines whether coverage is required.

In light of changes made by the administration, this policy brief provides an overview of vaccine coverage requirements by payer or program, as specified in law, regulations, and other policy guidance.2  As it shows, coverage requirements for all payers, except for vaccines covered under Medicare Part B, are currently linked to either ACIP and/or CDC vaccine recommendations. Therefore, a narrowing or removal of a vaccine recommendation, as was recently done for COVID-19, would mean that most insurers would no longer be required to provide no-cost coverage. (see Summary and Detailed Tables below).

Findings

Almost all payers are required to cover recommended vaccines at no-cost. This is currently the case for private insurance and employer-sponsored health plans, Medicaid, and Medicare. There is also a mandatory program for Medicaid-eligible and uninsured children – the Vaccines for Children Program – that provides recommended vaccines for free to eligible children (there is no such program for uninsured adults). The first requirement of coverage was in 1981, as part of Medicare Supplementary Insurance (Part B). The most recent was enacted in 2022, when the Inflation Reduction Act (IRA) required coverage of recommended vaccines under Medicare Part D and expanded Medicaid coverage for some adults not already covered.

Vaccine coverage requirements are linked to ACIP/CDC recommendations in almost every case. All payers, except under Medicare Part B, are required to provide no-cost coverage for vaccines recommended by ACIP/CDC. For example, most private insurers are required to cover vaccines that have, in effect, an ACIP recommendation. Vaccines covered under Medicare Part B are the exception, with four vaccines specifically authorized for coverage at no cost in statute.

The point at which a vaccine is considered “recommended” for purposes of requiring no-cost coverage varies somewhat by payer, and in some cases has been determined through subsequent rule-making or federal policy. For private insurers, Medicare Part D, and Medicaid expansion, the requirement is tied to an ACIP recommendation that has been adopted by the CDC Director, as specified in final regulations or guidance. For traditional Medicaid and CHIP, an ACIP recommendation is sufficient. For purposes of the Vaccines for Children Program, the list specified by ACIP determines what is included.

If ACIP or CDC vaccine recommendations were to be narrowed or removed, as was recently done in the case of COVID-19, most payers would no longer be required to provide no-cost coverage. On May 27, Secretary Kennedy announced that the COVID-19 vaccine was no longer recommended for healthy children, ages six months to 17 years, or for healthy pregnant women (COVID-19 vaccines were previously recommended for all children ages six months or older and pregnancy had previously been considered a condition that put people at increased risk for moderate or severe COVID-19 disease). This means that insurers will no longer be required to provide free vaccines for these populations unless they have an underlying health condition that places them at higher risk (in the case of children, the CDC subsequently revised the pediatric vaccine schedule to base the recommendation on “shared clinical decision-making”, which means free insurance coverage should be required if a doctor recommends a child be vaccinated based on that child’s individual circumstance).

Table 1: Summary of Vaccine Coverage Requirements by Payer/Program
Payer/ProgramCoverage Requirement Linked to CDC/ACIP?Date When Requirement First Enacted3
Private/Employer-Sponsored PlansYes2010
Medicare Part BNoVariable by vaccine, starting in 1981
Medicare Part DYes2022
Medicaid/CHIPYes2010 (expansion), 2022 (traditional/CHIP)
Vaccines for ChildrenYes1993
Uninsured AdultsN/AN/A
Table 2: Detailed Overview of Vaccine Coverage Requirements by Payer/Program
Payer/ProgramCoverage Requirement
Private/Employer-sponsored plans4,5The Affordable Care Act requires that issuers shall, at a minimum, provide coverage for and shall not impose any cost-sharing requirements for immunizations that have in effect an ACIP recommendation.

Per final ACA regulations, immunizations for routine use in children, adolescents, and adults are considered “in effect” once adopted by the CDC Director.  A recommendation is considered to be for “routine use” if it appears on the immunization schedules of the CDC.

Medicare Part B6Medicare Part B is required to cover pneumococcal (1981), hepatitis B (1984), influenza (1993) and COVID-19 (2020) vaccines without cost sharing, as specified in Title XVIII of the Social Security Act. This requirement is not linked to ACIP or CDC.
Medicare Part D7Medicare Part D is required to cover at no cost all adult vaccines recommended by ACIP (other than those required by law to be covered under Medicare Part B), as specified in the Inflation Reduction Act of 2022.

Per CMS guidance, this no-cost coverage requirement occurs once an ACIP recommendation is adopted by the CDC Director and posted on the CDC website (all categories of ACIP recommendations are included, not just routine use)

Medicaid/CHIP8Traditional Medicaid/CHIP: The Inflation Reduction Act requires state Medicaid and CHIP programs to cover adult vaccines recommended by ACIP, and their administration, without cost sharing. Per CMS guidance, the IRA coverage requirement is not limited to vaccines that ACIP includes on immunization schedules or recommends for routine use.

Medicaid expansion: Alternative Benefit Plans must cover vaccines recommended by ACIP for routine use in children, adolescents, and adults that have in effect a recommendation from ACIP with respect to the individual involved. A recommendation is considered in effect after it has been adopted by the CDC Director, and a recommendation is considered to be for routine use if it is listed on the CDC immunization schedule.

Medicaid/CHIP children: Medicaid’s EPSDT benefit requires states to cover all vaccines on the CDC/ACIP pediatric immunization schedule without cost sharing for children in Medicaid and Medicaid-expansion CHIP (M-CHIP). Any other vaccines not recommended by ACIP would have to be covered under EPSDT if deemed medically necessary. Medicaid and M-CHIP children generally receive their vaccines through the VFC. Separate state CHIP programs must cover all vaccines recommended by ACIP with no cost sharing.

Vaccines for Children9Section 1928 of the Social Security Act, as amended by the Omnibus Budget Reconciliation Act of 1993, created the Vaccines for Children Program which requires that the Secretary of HHS shall use, for the purpose of the purchase, delivery, and administration of pediatric vaccines, the recommended pediatric vaccine list established by ACIP for eligible children (Medicaid-eligible, uninsured, underinsured, and American Indian/Alaska Native children age 18 and younger). ACIP also establishes the pediatric vaccine schedule.
Uninsured10There is no guaranteed program that provides no-cost vaccines to uninsured adults. Rather, there is a discretionary federal program – the 317 program – that, based on funding, can provide grants to states to support immunization infrastructure and provision of recommended vaccines to uninsured adults.
Endnotes
  1. For example, the FDA recently announced planned changes to the criteria used to approve COVID-19 vaccines, Secretary of Health and Human Services, Robert F. Kennedy Jr. narrowed existing COVID-19 vaccine recommendations and also reconstituted the membership of ACIP.

    ← Return to text

  2. Also see: https://www.kff.org/coronavirus-covid-19/issue-brief/vaccine-coverage-pricing-and-reimbursement-in-the-u-s/https://advisory.avalerehealth.com/wp-content/uploads/2023/10/Guide-to-Vaccine-Coverage-Policies.pdfhttps://www.healthaffairs.org/content/forefront/vaccine-policy-crisis-secretary-kennedy-dismisses-entire-advisory-committee.

    ← Return to text

  3. The date in which the requirement takes effect may differ from date first enacted by law.

    ← Return to text

  4. Private insurance requirements pertain only to non-grandfathered plans and in-network providers.

    ← Return to text

  5. Sources: Patient Protection and Affordable Care ActFinal Rule: Coverage of Certain Preventive Services Under the Affordable Care Act; CMS, Affordable Care Act Implementation FAQs - Set 12

    ← Return to text

  6. Sources: Title XVIII of the Social Security Act, §410.57MedPAC, Medicare vaccine coverage and payment.

    ← Return to text

  7. Sources: Inflation Reduction ActCMS, Contract Year 2023 Program Guidance Related to Inflation Reduction Act Changes to Part D Coverage of Vaccines and InsulinCMS, REVISION - Contract Year 2023 Program Guidance Related to Inflation Reduction Act Changes to Part D Coverage of Vaccines.

Novavax stock slips as Citi issues Sell rating

 Novavax (NVAX) stock dropped after Citi issued a Sell rating, citing concerns over its respiratory vaccine-focused pipeline.

https://seekingalpha.com/news/4459116-novavax-stock-slips-citi-issues-sell-rating

UBS upgrades Alkermes stock rating on orexin treatment potential

 UBS upgraded Alkermes (NASDAQ:ALKS) from Neutral to Buy on Tuesday, raising its price target to $42.00 from $33.00. The upgrade reflects UBS’s growing confidence in the company’s orexin receptor drug candidate ALKS-2680 for narcolepsy and idiopathic hypersomnia treatment. 

UBS analyst commentary indicates that a recent physician survey strengthened the firm’s outlook on ALKS-2680’s market positioning. The drug candidate appears well-positioned to potentially establish itself as an attractive treatment option in sleep disorders, according to the research note.

The current stock valuation prices in approximately $1.2 billion in 2030 estimated sales, compared to UBS’s base case projection of $1.8 billion. This base case includes $350 million specifically for ALKS-2680, with the remainder attributed to Alkermes’ existing business portfolio. With a market capitalization of $4.85 billion and a P/E ratio of 15.08,

UBS notes that three key mid/late-stage orexin clinical trial results are expected in the second half of the year from Alkermes, Takeda, and Centessa Pharmaceuticals. These upcoming data readouts could generate broader market excitement for the entire orexin drug class.

The price target increase represents a 27% upside from the previous $33.00 target, signaling UBS’s more bullish stance on Alkermes’ growth prospects in the sleep disorder treatment market. 

https://www.investing.com/news/analyst-ratings/ubs-upgrades-alkermes-stock-rating-on-orexin-treatment-potential-93CH-4098594

Supreme Court Gets First Chance to Weigh in on Donald Trump's Tariffs



Two small toy companies have petitioned the U.S. Supreme Court to overturn President Donald Trump's global tariffs, arguing that he exceeded his authority under the International Emergency Economic Powers Act (IEEPA).

The Supreme Court's decision on whether to hear the case could have significant implications for the scope of executive power in trade policy.

Trump's tariffs led to global market turmoil, particularly after the president rolled out hefty tariffs targeting almost every U.S. trading partner on April 2, which he dubbed "liberation day." The president has since backtracked on the initial announcement, but the U.S. tariff policy remains in flux.

Tuesday's petition comes from an earlier case in which a federal judge sided with two Chicago-based toy companies and ruled that Trump overstepped his powers when invoking the IEEPA to impose tariffs. The Trump administration appealed the ruling, which was limited to the two toy companies, after which the plaintiffs went to the U.S. Supreme Court.

"In light of the tariffs' massive impact on virtually every business and consumer across the nation, and the unremitting whiplash caused by the unfettered tariffing power the president claims, challenges to the IEEPA tariffs cannot await the normal appellate process [even on an expedited timeline]," the family owned toy companies, Learning Resources Inc. and hand2mind Inc., said in their petition to the high court.

"There is ample reason for this Court to grant certiorari before judgment now so this case can be briefed over the summer and argued as soon as possible."

Trump's global tariffs were also blocked by the U.S. Court of International Trade (USCIT) in a separate case last month, but a federal appeals court quickly stayed the ruling, allowing the tariffs to remain in place while legal proceedings play out.

The USCIT's three-judge panel said in its summary judgment: "The question in the two cases before the court is whether the International Emergency Economic Powers Act of 1977 ['IEEPA'] delegates these powers to the President in the form of authority to impose unlimited tariffs on goods from nearly every country in the world."

https://www.newsweek.com/supreme-court-gets-first-chance-weigh-donald-trump-tariffs-2086898